ArticleBMC geriatrics2026
Association between stride length variability and osteosarcopenia in community-dwelling older women: a cross-sectional study.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOsteosarcopenia, the coexistence of sarcopenia and low bone mass, raises the risk of falls, fractures, and functional decline, yet its diagnosis depends on dual-energy X-ray absorptiometry (DXA) and muscle function testing, which are difficult to apply routinely in the community. Whether gait variability, a marker of neuromuscular control, is associated with osteosarcopenia and adds information beyond mean gait measures is unknown in Korean community-dwelling older women. We examined this association and the discriminative ability of gait variability for osteosarcopenia.
methodsIn this cross-sectional study, 190 community-dwelling women aged 65 years or older were classified by DXA and the 2019 Asian Working Group for Sarcopenia criteria into normal (n = 32), osteoporosis (n = 118), and osteosarcopenia (n = 40) groups. Spatiotemporal gait parameters and their trial-to-trial variability, expressed as the coefficient of variation (CV), were measured during overground walking with the OptoGait system. Binary logistic regression and receiver operating characteristic (ROC) analyses were performed.
resultsFrom the normal to the osteosarcopenia group, gait speed and stride length decreased while stride length CV increased. After adjustment for age and confounders, shorter stride length, higher stride length CV, and lower body mass index (BMI) were each independently associated with osteosarcopenia (all p ≤ 0.013). A combined model of these three variables discriminated osteosarcopenia with an area under the curve of 0.83 (sensitivity 75.0%, specificity 81.3%).
conclusionsIn this cross-sectional sample, gait variability, combined with stride length and BMI, was associated with osteosarcopenia and may offer a practical, noninvasive screening adjunct to prioritize older women for confirmatory DXA assessment. Prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.